Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy.
BACKGROUND
The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid (lecithin, Meriva(®)) formulation (Norflo(®) tablet) on visual acuity and retinal thickness in patients with acute or chronic central serous chorioretinopathy.


METHODS
Visual acuity was assessed by ophthalmologic evaluation, and optical coherence tomography was used to measure retinal thickness. Norflo tablets were administered twice a day to patients affected by central serous chorioretinopathy. The study included 18 eyes from 12 patients who completed a 6-month follow-up period. Visual acuity before and after Norflo treatment was the primary endpoint. The secondary endpoints were neuroretinal or pigment epithelial detachment, as measured by optical coherence tomography.


RESULTS
After 6 months of therapy, 0% of eyes showed reduction in visual acuity, 39% showed stabilization, and 61% showed improvement. The improvement was statistically significant (P = 0.08). After 6 months of therapy, 78% of eyes showed reduction of neuroretinal or retinal pigment epithelium detachment, 11% showed stabilization, and 11% showed an increase.


CONCLUSIONS
Our results, albeit preliminary, show that curcumin administered as Norflo tablets is efficacious for the management of central serous chorioretinopathy, a relapsing eye disease, and suggest that bioavailable curcumin is worth considering as a therapeutic agent for the management of inflammatory and degenerative eye conditions, including those that activate the retinal microglia.
Private Practice, Milan, Italy.
Fabio
F
Mazzolani